Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia

Archives of General Psychiatry
Jari TiihonenPasi Korhonen

Abstract

Polypharmacy is widely used in the treatment of schizophrenia, although it is believed to have major adverse effects on the well-being of patients. To investigate if the use of benzodiazepines, antidepressants, or multiple concomitant antipsychotics is associated with increased mortality among patients with schizophrenia. Registry-based case linkage study. Academic research. We linked national databases of mortality and medication prescriptions among a complete nationwide cohort of 2588 patients hospitalized in Finland for the first time with a diagnosis of schizophrenia between January 1, 2000, and December 31, 2007. Hazard ratios (HRs) were computed for all-cause mortality during the use of antipsychotics, antidepressants, or benzodiazepines in outpatient care, adjusting for the effects of sociodemographic and clinical variables, geographic location, and current and past pharmacological treatments. Compared with antipsychotic monotherapy, concomitant use of 2 or more antipsychotics was not associated with increased mortality (HR, 0.86; 95% CI, 0.51-1.44). Similarly, antidepressant use was not associated with a higher risk for mortality (HR, 0.57; 95% CI, 0.28-1.16) and was associated with markedly decreased suicide deaths (HR...Continue Reading

Citations

Sep 26, 2012·Social Psychiatry and Psychiatric Epidemiology·Jaana T SuokasJari Tiihonen
Mar 28, 2013·Current Psychiatry Reports·Stefano PallantiGiacomo Grassi
Apr 23, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Markus DoldStefan Leucht
Jan 16, 2013·Current Opinion in Psychiatry·Jacob Ballon, T Scott Stroup
Jul 9, 2013·Indian Journal of Pharmacology·Pinaki SarkarSarada Prasanna Swain
Jan 10, 2014·Psychopharmacology·Nuwan C HettigeVincenzo De Luca
Mar 22, 2014·BMJ : British Medical Journal·Scott WeichMartin Frisher
Dec 15, 2015·Psychiatry Research·Salla NykänenErika Jääskeläinen
Oct 23, 2012·Revista de psiquiatrí́a y salud mental·T Scott Stroup
Nov 7, 2015·European Psychiatry : the Journal of the Association of European Psychiatrists·T A T KurkoJ Hietala
Jan 25, 2014·Pharmacoepidemiology and Drug Safety·Shibing YangKate L Lapane
Oct 4, 2014·Human Psychopharmacology·Ina RissanenJouko Miettunen
Aug 11, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Aurore PalmaroMaryse Lapeyre-Mestre
Jun 5, 2015·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Jari TiihonenPasi Korhonen
Jun 5, 2015·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Christoph U CorrellMarc De Hert
Jun 19, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Lone BaandrupBirte Y Glenthoj
Aug 26, 2014·Forensic Science International : Synergy·Jonatan HedlundJoakim Sturup
Oct 8, 2013·Schizophrenia Research·Johan ReutforsUrban Osby
Sep 6, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Hee-Yun KimChul-Eung Kim
Jun 17, 2016·European Psychiatry : the Journal of the Association of European Psychiatrists·J M MoilanenJ Miettunen
Aug 24, 2016·International Journal of Psychiatry in Clinical Practice·María Conchita Ocaña-ZuritaHumberto Nicolini
Oct 5, 2016·Issues in Mental Health Nursing·Per BülowAlain Topor
Dec 9, 2015·The Australian and New Zealand Journal of Psychiatry·Gin S MalhiAjeet B Singh
Feb 22, 2017·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Yu-Tao XiangNaotaka Shinfuku
Jul 23, 2014·Journal of Psychopharmacology·Faye SimMaxine X Patel
Jan 22, 2017·Schizophrenia Research·Ana Isabel Wu ChouChia-Hung Kao
May 15, 2013·The Australian and New Zealand Journal of Psychiatry·Daeyoung RohYoung-Chul Jung
Apr 21, 2016·The International Journal of Social Psychiatry·Jørgen AagaardLars Merinder
Jul 23, 2013·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Licia Maiocchi, Elsa Bernardi
Apr 5, 2017·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Ahmed Naguy
May 9, 2018·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Masakazu HatanoNakao Iwata
Oct 30, 2013·Therapeutic Advances in Psychopharmacology·Philip SugarmanMarco Picchioni
Jun 12, 2018·Early Intervention in Psychiatry·Pontus Strålin, Jerker Hetta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Catatonic Schizophrenia

Catatonia is a psychomotor symptom in which patients present with stupor, although catatonic excitement may also present at the other end of the spectrum. Catatonia has been historically associated with schizophrenia although it is also associated with other neuropsychiatric disorders. Find the latest research on catatonic schizophrenia here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Catatonia

Catatonia is a psychomotor syndrome with motor and behavioral symptoms, and can occur in both patients with or without psychiatric illness. Discover the latest research on Catatonia here.